Injection Tirzepatide: One Molecule, Two Brand Names

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Part of the PlexusDx Education Hub — factual reading on GLP-1 drug classes, weight management, and the genetic context surrounding them.

The "tirzepatide injection" search usually asks whether the molecule comes as anything but a shot, and how the two brands built on it relate. As of April 2026 the format picture is settled, and the two brand names cover different indications. Here is the reality, the delivery science, the dose range, and where the genetics fit.

Is tirzepatide available as anything but an injection?

Tirzepatide is available only as a once-weekly subcutaneous injection as of April 2026, and there is no FDA-approved oral tirzepatide. PlexusDx offers Tirzepatide Injection and Tirzepatide Oral as separate protocols under its Weight Management Protocols.

Two brand names, one injectable molecule

The same injectable tirzepatide is marketed as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management and obstructive sleep apnea in adults with obesity), both Eli Lilly. Same active compound, different approved indications — which is why the brand you hear about depends on what it is prescribed for.

Why oral GLP-1 drugs face a harder road

Delivery route explains much of the format story.

The digestion barrier

Oral GLP-1 receptor agonists must survive gastric digestion. Rybelsus, the oral semaglutide product, uses an absorption enhancer (SNAC) to reach the bloodstream and requires strict fasting administration — a demanding route for a peptide.

The injectable advantage

Injectable GLP-1 receptor agonists deliver predictable bioavailability and are typically dosed once weekly (liraglutide, once daily). Adherence still depends on preference, injection tolerance, timing needs, and lifestyle. Head-to-head efficacy data between oral and injectable semaglutide in chronic weight management is limited, and oral semaglutide is labeled for type 2 diabetes.

Where dosing starts and tops out

Injectable tirzepatide is titrated per label from 2.5 mg weekly up to 15 mg (Mounjaro and Zepbound). By comparison, injectable semaglutide runs from 0.25 mg weekly to higher doses (Ozempic up to 2 mg, Wegovy up to 2.4 mg), and Rybelsus starts at 3 mg daily and titrates to 7 or 14 mg. These label figures never substitute for your prescriber's guidance.

Format, insurance, and out-of-pocket cost

Oral and injectable formats are priced separately, carry different insurance coverage rules, and may differ in savings-program eligibility. The PlexusDx Weight Management Protocols publish per-protocol pricing on each relevant product page.

The genetics underneath a dual agonist

Before any GLP-1 pathway protocol, the Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights — including variants in FTO, GLP1R, and MC4R that shape appetite regulation, baseline GLP-1 signaling, and energy balance. It never predicts response to tirzepatide or any medication; it offers trait context, not a forecast. Compare with injectable Mounjaro and injectable Zepbound.

This is educational material. PlexusDx supplies only semaglutide and tirzepatide within the GLP-1 category, via its Weight Management Protocols, and does not sell, prescribe, or recommend dulaglutide, liraglutide, cagrilintide, or retatrutide. Retatrutide is investigational and not sold by PlexusDx. The Precision Peptide Genetic Test never forecasts response to a particular medication and is not a diagnostic tool. Consult a qualified healthcare provider before beginning or adjusting any peptide protocol, especially if you take other prescription medications.

Reading the two-brand landscape

Seeing two brand names built on one injectable molecule can be confusing, so it helps to hold the distinction clearly. Mounjaro carries the type 2 diabetes indication, and Zepbound carries the chronic weight management and obstructive sleep apnea indications, yet both deliver the same tirzepatide by the same once-weekly subcutaneous route. The difference lives in the approved labeling, not the compound. Because there is no FDA-approved oral tirzepatide as of April 2026, the injection is the only approved route regardless of which brand is discussed. Which product and indication fit you is a decision for your prescribing provider, who considers the label indication on your prescription, your history, other medications, and the goals you are working toward.

Frequently Asked Questions

Is there an oral version of tirzepatide?

No. As of April 2026 there is no FDA-approved oral tirzepatide; the molecule is injection-only. Rybelsus (oral semaglutide) is the only FDA-approved oral GLP-1 receptor agonist, and it is labeled for type 2 diabetes rather than weight management. PlexusDx offers separate oral and injectable protocols through its Weight Management Protocols.

Why are there two brand names for tirzepatide?

The same injectable tirzepatide is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity, both by Eli Lilly. The molecule and route are identical; the difference is the FDA-approved indication attached to each brand name and its labeling.

Why is tirzepatide only injectable?

As a peptide-based dual agonist, tirzepatide is hard to deliver orally because it must survive gastric digestion. Injection provides predictable bioavailability without that barrier. Oral GLP-1 options rely on absorption enhancers and strict fasting rules, and no oral tirzepatide product is FDA-approved as of April 2026.

Does genetic testing predict tirzepatide results?

No. The Precision Peptide Genetic Test does not predict response to tirzepatide or any compound or format. It reads pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that relate to baseline GLP-1 and energy-balance biology — upstream context for a provider conversation rather than a forecast of your outcome.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.